Published in Medicine and Law Weekly, March 11th, 2005
The study reported that a subconjunctival delivery of CA4P, a vascular targeting agent (VTA), induces an extensive dose-dependent reduction in blood vessel count leading to significant tumor reduction with no evidence of corneal, lenticular, choroidal or retinal toxicity. CA4P is involved in seven ongoing human oncology trials in the United States and Europe.
"These data provide further evidence of CA4P's ability to attack aberrant blood vessels...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medicine and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.